Who
Heather D. Turner
Director
Company insider
Files Form 4 as: Director, Terns Pharmaceuticals; Director, Avalyn Pharma; Chief Executive Officer, LB Pharmaceuticals; Chief General Counsel, Lyell Immunopharma; EVP, General Counsel & Sec., Sangamo Therapeutics; Former EVP, GC & Sec., Atara Biotherapeutics; SVP, Gen. Counsel & Secretary, Orexigen Therapeutics.
In numbers
- Trades disclosed
- 78
- Buys
- 0
- Sells
- 7
- Bought
- $0
- Sold
- $2.9M
- Companies
- 7
- Companies where not an officer
- 2
- First trade
- 25 Jun 2007
- Last trade
- 5 May 2026
- Last filed
- 5 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —64,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,697 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —45,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —64,000 | filing |
| 5 May 2026filed 5 May 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,697 | filing |
| 29 Apr 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,978 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | AVLN Avalyn Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,978 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | Terns Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,697 at $0.00 | filing |
| 1 Feb 2026filed 2 Feb 2026 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —1,697 at $0.00 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —175,706 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —175,706 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,857 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,857 | filing |
| 10 Sep 2025filed 12 Sep 2025 | LBRX LB Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —971,828 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 18 Nov 2024filed 19 Nov 2024 | Terns Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —64,000 at $0.00 | filing |
| 16 Mar 2022filed 18 Mar 2022 | LYEL Lyell Immunopharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 25 Feb 2019filed 27 Feb 2019 | Sangamo Therapeuticsoption or derivative | SEC FORM 4 Code A | —115,500 at $0.00 | filing |
| 25 Feb 2019filed 27 Feb 2019 | Sangamo Therapeutics | SEC FORM 4 Code A | —19,250 at $0.00 | filing |
News
Head to Head Analysis: Atara Biotherapeutics (NASDAQ:ATRA) and Valneva (NASDAQ:VALN)ATRA · dailypolitical.com · 23 Oct 2026
0 headlines in the last 90 days name Heather D. Turner; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.